Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Eton Pharmaceuticals, Inc.
Report date April 12, 2021 · Filed April 12, 2021
Section 16 reporting ended · disclosed 2021-04-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,982,000 |
Reported balance
After 2021-04-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-04-12 · Sale · Disposed 1,518,000 · Balance 1,982,000 F1: On April 12, 2021, Harrow Health, Inc., a Delaware corporation (the "Company"), closed the previously announced underwritten public offering of 1,518,000 shares of common stock of Eton Pharmaceuticals, Inc. at a public offering price of $7.00 per share, including 198,000 shared issued pursuant to the full exercise by the underwriter, National Securities Corporation, of its over-allotment option. The gross proceeds to the Company from the offering were approximately $10.6 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 12, 2021, Harrow Health, Inc., a Delaware corporation (the "Company"), closed the previously announced underwritten public offering of 1,518,000 shares of common stock of Eton Pharmaceuticals, Inc. at a public offering price of $7.00 per share, including 198,000 shared issued pursuant to the full exercise by the underwriter, National Securities Corporation, of its over-allotment option. The gross proceeds to the Company from the offering were approximately $10.6 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 12, 2021 Filed Apr 12, 2021 23:55 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | SaleCommon Stock | 1,518,000 | $7.00 | $10,626,000.00 |
DisclosureSEC source: 0001493152-21-008584 · ownership.xml · nonDerivative · entry 1 HARROW HEALTH, INC. · CIK 0001360214 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,982,000 F1 · security: On April 12, 2021, Harrow Health, Inc., a Delaware corporation (the "Company"), closed the previously announced underwritten public offering of 1,518,000 shares of common stock of Eton Pharmaceuticals, Inc. at a public offering price of $7.00 per share, including 198,000 shared issued pursuant to the full exercise by the underwriter, National Securities Corporation, of its over-allotment option. The gross proceeds to the Company from the offering were approximately $10.6 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.